Other Events ·
LENZ Therapeutics cuts headcount by ~75%, announces CEO transition and $5M restructuring charges
LENZLENZ Therapeutics, Inc.
LENZ Therapeutics announced a strategic reorganization to prioritize consumer marketing and reduce operating expenses, including decreasing its workforce by approximately 75% to about 40 full-time employees. The company expects to incur non-recurring charges of approximately $5 million for severance and related benefits, substantially all in the fourth quarter of 2026. Concurrently, President and CEO Eef Schimmelpennink will transition from his roles effective December 1, 2026, with CFO Daniel Chevallard appointed as Interim President and CEO. The filing also reported third-quarter product sales of $2.6 million, a 50% increase over the prior quarter. LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ for presbyopia.